A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Vyaire Medical Advances Surgical Sedation Safety with Novel Airway Technology for All Patient Risk Levels

The new SuperNO2VA™ Et mask establishes a new care paradigm for surgical options by maintaining an open airway and providing real-time exhaled carbon dioxide monitoring, decreasing sedation risk before, during and after surgery

What To Know

  • Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of SuperNO2VA™ Et, a mask that utilizes breakthrough technology to stent the airway open, thus avoiding airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), which is particularly important for high-risk patients.
  • “As the company inspired and empowered to elevate the quality of breathing, SuperNO2VA™ Et is an obvious yet critical piece of our innovation strategy and evolution,”.

Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of SuperNO2VA™ Et, a mask that utilizes breakthrough technology to stent the airway open, thus avoiding airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), which is particularly important for high-risk patients.

Vyaire Medical notes it uniquely maintains airway patency while delivering precise and consistent oxygenation to patients during deep sedation procedures, helping reduce hypoxemia and hypoventilation. SuperNO2VA™ Et provides increased flexibility by providing continuous patient oxygenation before, during and after surgery, and transforms surgical practice by allowing more patients to have procedures under sedation.

“At Vyaire, we are committed to imagining new possibilities in the ways we can support breathing. SuperNO2VA™ Et does just that by removing some of the tangible risks of deep sedation through proprietary airway management technology and real-time clinical measurements to reduce complications,” said Gaurav Agarwal, chief executive officer, Vyaire. “Through this innovation, we envision reducing the need for general anesthesia and the associated complications, including extended procedure times, hospital stays and their burdens on healthcare systems.”

SuperNO2VA™ Et reduces hypoxemia by 75 percent and airway intervention by 65 percent compared to current standard of care.[i],[ii] It also allows for effective pre-oxygenation and rescue ventilation without the need for additional equipment, and eliminates the use and associated costs of a separate mask, endotracheal tube, laryngoscope and intubation.

“SuperNO2VA™ Et brings a new standard to the way surgeries can be performed for patients,” said Steven H. Cataldo, MD, director of anesthesiology at CareMount Medical and director of anesthesia services at Yorktown Center for Specialty Surgery. “With this technology, we are able to rethink how and where we operate, with decreased risks, procedure times and associated costs. Even high-risk patients can have reduced recovery times, providing them a safer and better overall care experience.”

“As the company inspired and empowered to elevate the quality of breathing, SuperNO2VA™ Et is an obvious yet critical piece of our innovation strategy and evolution,” said Agarwal. “We will continue to bring new-to-world technology to market to advance breathing solutions on behalf of customers and patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy